Background
An updated systematic review and meta‐analysis was conducted to compare radiofrequency ablation (RFA) versus repeat hepatectomy (RH) for patients with recurrent hepatocellular carcinoma (rHCC) after a previous liver resection.
Methods
PubMed, EMBASE, and Cochrane databases were searched from inception to October 2021 for randomized controlled trials and propensity‐score matched studies. Individual participant survival data of disease‐free survival (DFS) and overall survival (OS) were extracted and reconstructed followed by one‐stage and two‐stage meta‐analysis. Secondary outcomes were major complications and length of hospital stay (LOHS).
Results
A total of seven studies (1317 patients) were analysed. In both one‐stage and two‐stage meta‐analysis, there was no significant difference in OS between the RFA and RH cohorts (Hazard Ratio (HR) 1.15, 95% CI 0.98–1.36, P = 0.094 and HR 1.12, 95% CI 0.77–1.64, P = 0.474 respectively), while the RFA group had a higher hazard rate of disease recurrence compared to the RH group (HR 1.30, 95% CI 1.13–1.50, P < 0.001 and HR 1.31, 95% CI 1.09–1.57, P = 0.013, respectively). RFA was associated with fewer major complications and shorter LOHS versus RH (Odds Ratio 0.34, 95% CI 0.15–0.76, P = 0.009 and Weighted Mean Difference − 4.78, 95% CI − 6.30 to − 3.26, P < 0.001, respectively).
Conclusions
RH may be associated with superior DFS for rHCC, at the expense of higher morbidity rate and longer LOHS. However, OS is comparable between both modalities. As such, these techniques may be utilized as complementary strategies depending on individual patient and disease factors. Large‐scale, randomized, prospective studies are required to corroborate these findings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.